Cure8 news brief
Parents and clinicians often seek ways to help children feel better quickly after starting biologic therapy. This study suggests adding a Crohn’s disease exclusion diet with partial enteral nutrition may shorten the time to symptom improvement, though objective inflammation resolved at similar rates.
Pediatric patients with Crohn's disease, parents and caregivers, pediatric gastroenterologists, and clinicians managing children starting biologic therapy.
Adding the Crohn’s disease exclusion diet with partial enteral nutrition to first-line anti-TNF biologic therapy was associated with faster symptomatic improvement (greater drop in wPCDAI and shorter times to clinical response/remission) in a retrospective single-center pediatric cohort, but the diet did not lead to faster normalization of inflammatory markers (ESR, CRP, fecal calprotectin) or higher rates of mucosal healing compared with biologics alone.
The study was small (27 diet + biologic, 13 biologic-only) and nonrandomized, so observed symptom benefits could reflect unmeasured differences between groups.
This was a retrospective real-world analysis from a single pediatric center in Argentina reporting time-to-event outcomes, endoscopy, and biomarker data; the primary signal was symptomatic improvement rather than objective inflammation.
The authors highlight limitations including sample size and lack of random assignment and call for larger studies to determine whether earlier symptom control translates into durable advantages.
If families or clinicians are considering adding exclusion diet/partial enteral nutrition to biologic therapy, this study suggests it may speed symptomatic relief but should not be assumed to accelerate biomarker or endoscopic healing based on current evidence.
This is a small, retrospective, single-center cohort study (nonrandomized); differences between groups may reflect selection bias. The study found symptom improvements but no significant differences in fecal calprotectin normalization or mucosal healing. Larger randomized studies are needed to confirm whether adjunctive dietary therapy provides lasting benefits.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
